{
    "clinical_study": {
        "@rank": "106157", 
        "brief_summary": {
            "textblock": "This is a non-randomized, phase 1, study with the primary objective of determining the\n      toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10\n      minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in\n      lightly or heavily pre-treated patients with locally advanced or metastatic cancer."
        }, 
        "brief_title": "ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer", 
        "condition": [
            "Metastases", 
            "Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic or cytologic diagnosis of metastatic or locally advanced cancer\n\n          -  Prior chemotherapy is allowed\n\n          -  Adequate bone marrow, liver and kidney function\n\n        Exclusion Criteria:\n\n          -  Prior treatment with ALIMTA\n\n          -  Brain metastasis\n\n          -  Pregnancy or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 29, 2002", 
        "id_info": {
            "nct_id": "NCT00034463", 
            "org_study_id": "1310", 
            "secondary_id": "H3E-MC-JMAS"
        }, 
        "intervention": [
            {
                "intervention_name": "ALIMTA", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "folic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "multi-vitamins", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vitamin B Complex", 
                "Vitamins", 
                "Pemetrexed"
            ]
        }, 
        "keyword": [
            "metastatic cancer", 
            "chemotherapy"
        ], 
        "lastchanged_date": "July 18, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034463"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2006"
    }, 
    "geocoordinates": {
        "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.": "29.424 -98.494"
    }
}